TY - JOUR
T1 - Validation of the Edmonton Symptom Assessment System
T2 - Ascites Modification
AU - Mori, Masanori
AU - Morita, Tatsuya
AU - Yokomichi, Naosuke
AU - Nitto, Akihiro
AU - Takahashi, Naoko
AU - Miyamoto, Shingo
AU - Nishie, Hiroyuki
AU - Matsuoka, Junji
AU - Sakurai, Hiroki
AU - Ishihara, Tatsuhiko
AU - Tarumi, Yoko
AU - Ogawa, Asao
N1 - Funding Information:
The authors declare no conflicts of interest. This study was in part supported by the Japan Society for the Promotion of Science KAKENHI grant number JP16K15418 . The authors would like to thank all participants and participating institutions for taking part in this study. The authors thank Keiji Koguchi, MD (Fukuyama City Hospital), Cheryl Nekolaichuk, PhD (Division of Palliative Care Medicine, Department of Oncology, University of Alberta), and Sharon Watanabe, MD (Division of Palliative Care Medicine, Department of Oncology, University of Alberta) for their assistance with this project. The authors also thank Drs. Tomoko Sakai and Mitsunori Miyashita (Tohoku University) for their assistance in introducing the Japanese version of the EORTC QLQ-PAN26.
Publisher Copyright:
© 2018 American Academy of Hospice and Palliative Medicine
PY - 2018/6
Y1 - 2018/6
N2 - Context: Few patient-reported outcomes are available to measure the symptoms associated with malignant-related ascites in patient care and clinical research. Although the Edmonton Symptom Assessment System: Ascites Modification (ESAS:AM) is a brief tool to measure symptoms associated with malignant-related ascites, it remains to be fully validated. Objectives: The objective of the study was to validate the ESAS:AM in Japanese cancer patients. Methods: We assessed the internal consistency, test-retest reliability, concurrent validity, and construct validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS:AM, M.D. Anderson Symptom Inventory, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30, and abdominal pain/ascites subscales of the EORTC Core Quality of Life Questionnaire, 26-item pancreatic cancer module. Results: Cronbach's alpha coefficient of the ESAS:AM was 0.89. The intraclass correlation coefficient on test-retest examination of its total score was 0.93 (P < 0.001). Pearson correlation coefficients of the total score of the ESAS:AM with the total score of the M.D. Anderson Symptom Inventory and abdominal pain/ascites subscales of the EORTC Core Quality of Life Questionnaire, 26-item pancreatic cancer module ranged from 0.44 to 0.81 (P < 0.001) and those with global health status/quality of life and functional subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 ranged from −0.40 to −0.61 (P < 0.001). The total scores of the ESAS:AM were significantly higher in 20 patients with symptomatic ascites (34 [SD, 26]) than 267 patients without symptomatic ascites (23 [SD, 19]) (P = 0.018). Conclusion: The ESAS:AM is a reliable and valid tool for measuring symptoms associated with malignant-related ascites and can be used in daily patient care and future epidemiological studies and clinical trials.
AB - Context: Few patient-reported outcomes are available to measure the symptoms associated with malignant-related ascites in patient care and clinical research. Although the Edmonton Symptom Assessment System: Ascites Modification (ESAS:AM) is a brief tool to measure symptoms associated with malignant-related ascites, it remains to be fully validated. Objectives: The objective of the study was to validate the ESAS:AM in Japanese cancer patients. Methods: We assessed the internal consistency, test-retest reliability, concurrent validity, and construct validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS:AM, M.D. Anderson Symptom Inventory, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30, and abdominal pain/ascites subscales of the EORTC Core Quality of Life Questionnaire, 26-item pancreatic cancer module. Results: Cronbach's alpha coefficient of the ESAS:AM was 0.89. The intraclass correlation coefficient on test-retest examination of its total score was 0.93 (P < 0.001). Pearson correlation coefficients of the total score of the ESAS:AM with the total score of the M.D. Anderson Symptom Inventory and abdominal pain/ascites subscales of the EORTC Core Quality of Life Questionnaire, 26-item pancreatic cancer module ranged from 0.44 to 0.81 (P < 0.001) and those with global health status/quality of life and functional subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 ranged from −0.40 to −0.61 (P < 0.001). The total scores of the ESAS:AM were significantly higher in 20 patients with symptomatic ascites (34 [SD, 26]) than 267 patients without symptomatic ascites (23 [SD, 19]) (P = 0.018). Conclusion: The ESAS:AM is a reliable and valid tool for measuring symptoms associated with malignant-related ascites and can be used in daily patient care and future epidemiological studies and clinical trials.
KW - Edmonton Symptom Assessment System: Ascites Modification
KW - cancer
KW - malignant-related ascites
KW - reliability
KW - validation
KW - validity
UR - http://www.scopus.com/inward/record.url?scp=85046855127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046855127&partnerID=8YFLogxK
U2 - 10.1016/j.jpainsymman.2018.03.016
DO - 10.1016/j.jpainsymman.2018.03.016
M3 - Article
C2 - 29581035
AN - SCOPUS:85046855127
SN - 0885-3924
VL - 55
SP - 1557
EP - 1563
JO - Journal of Pain and Symptom Management
JF - Journal of Pain and Symptom Management
IS - 6
ER -
